Editas Medicine, Inc. (EDIT)

US — Healthcare Sector
Peers: BEAM  CRSP  CRBU  VERV  NTLA  PRME  VRTX  DNA  ALLO  SANA 

Automate Your Wheel Strategy on EDIT

With Tiblio's Option Bot, you can configure your own wheel strategy including EDIT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EDIT
  • Rev/Share 0.3754
  • Book/Share 0.7515
  • PB 2.2886
  • Debt/Equity 0.4988
  • CurrentRatio 3.0752
  • ROIC -0.9041

 

  • MktCap 143986188.0
  • FreeCF/Share -2.592
  • PFCF -0.6688
  • PE -0.5686
  • Debt/Assets 0.1181
  • DivYield 0
  • ROE -1.6629

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation EDIT H.C. Wainwright -- Buy -- $3 April 28, 2025
Downgrade EDIT JP Morgan Neutral Underweight -- -- Dec. 16, 2024
Downgrade EDIT Chardan Capital Markets Buy Neutral -- -- Dec. 13, 2024
Downgrade EDIT Stifel Buy Hold $11 $3 Dec. 13, 2024
Downgrade EDIT Truist Buy Hold -- -- Dec. 13, 2024
Downgrade EDIT Wells Fargo Overweight Equal Weight $7 $4 Dec. 11, 2024

News

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
EDIT
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral

Editas Medicine, Inc. (NASDAQ:EDIT ) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Welcome to the last fireside for day 1 of the 2025 Bank of America Healthcare Conference. Thanks for joining this session with Editas.

Read More
image for news Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
EDIT
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.

Read More
image for news Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
EDIT
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Read More
image for news Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.

Read More
image for news Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?
EDIT
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
EDIT
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Negative

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
EDIT
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore O'Neill with us.

Read More
image for news Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
EDIT
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Negative

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

Read More
image for news Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
EDIT
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Neutral

Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Alexander Kelly - TD Cowen Alexander Kelly Hi everyone. I'm Alex Kelly.

Read More
image for news Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
EDIT
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.

Read More
image for news Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

About Editas Medicine, Inc. (EDIT)

  • IPO Date 2016-02-03
  • Website https://www.editasmedicine.com
  • Industry Biotechnology
  • CEO Dr. Gilmore O'Neill M.D.
  • Employees 246

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.